Navigation Links
Ranbaxy Commends New IMS Study Which Credits Generic Prescription Drugs With $1 Trillion Savings In U.S. Health Care Costs Over Past 10 Years

PRINCETON, N.J., Aug. 2, 2012 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI) today acknowledged an important, new study released by the Generic Pharmaceutical Association (GPhA) which further demonstrates the vital role played by the generic pharmaceutical industry in lowering prescription costs for consumers and the U.S. health care system.

The fourth annual Generic Drug Savings study reveals remarkable reductions in healthcare costs over the past 10 years (from 2002 to 2011). The research—conducted by the IMS Institute for Healthcare Informatics, the leading provider of market intelligence to the pharmaceutical and health care industries for over 55 years—reveals a $1 trillion savings to consumers, patients and the U.S. health care system due to the use of generic prescription drugs. The study found that in 2011 alone, the use of generic drugs in place of their branded counterparts generated nearly $193 billion in savings, an average of $1 billion every other day.

"We are proud of Ranbaxy's contribution to such a considerable record of savings for consumers and reduction in U.S. health care costs," said Venkat Krishnan, Senior Vice President and Regional Director – Americas.  "Through the diligent work of employees in every division of our company, Ranbaxy is committed to providing patients across the country with affordable and accessible, safe and effective generic prescription drugs that enhance their health and well-being."

He added, "Today, thousands of generic drugs are available in the U.S., and all are manufactured and inspected under the same strict guidelines as brand name drugs.  With every prescription filled (some 80 percent of all prescriptions written in 2011), patients taking generics receive the same medicine, with the same quality and result, but at a much lower cost. We are happy to be a part of the solution to the problem of escalating costs facing the U.S. health care system."

According to the GPhA study, the proven track record of savings for consumers using traditional generic drugs can be duplicated in the biopharmaceutical market. The approval of biosimilars will inject the competition needed in the biologic market to lower costs and provide significant savings for patients in need of these life saving treatments.

"We view biologics as the next generation of generic innovation, and Ranbaxy has been hard at work positioning itself as a player in this space. It is important that the FDA maintains its commitment to biosimilars and that it ensures a workable pathway for such life saving treatments in the U.S. market," Krishnan concluded.

Since the implementation of the Hatch-Waxman Act in 1984, which opened the door to the generic pharmaceutical industry, consumers and patients have had a steady stream of lower cost, safe and effective generic treatments.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company.  RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. health care system.

SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ranbaxy Announces U.S. FDA Approval of CIP-Isotretinoin NDA
2. ACEP Commends Congress For Passing Legislation That Addresses Drug Shortages As Well As "Bath Salts"
3. Boston Scientific Commends Congress on Passage of Bill Reauthorizing Medical Device User Fees
4. Pew Commends U.S. Congress for Passing FDA User Fee Legislation
5. AdvaMed Commends House Progress on Repealing Medical Device Tax
6. In Pilot Study, a Peptide Controls Blood Sugar in People with Congenital Hyperinsulinism
7. Concordia Study Indicates Obesity is Becoming the Nations Top Health Issue
8. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
9. French Government Agrees to Fund Study of the PneumRx RePneu Lung Volume Reduction Coil
10. Gentris Corporation Announces Collaboration to Study Blood Stability
11. New Study Reveals Wide Variation in Blood Transfusion Practices During Surgery
Post Your Comments:
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):